26 Flere grad 3/ 4 bivirkninger blev observeret for Docetaxel Winthrop monoterapi (55, 4%) sammenlignet med paclitaxel (23, 0%).
More grade 3/ 4 adverse events were observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).